Literature DB >> 1710463

Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma.

C E Sever1, J Locker.   

Abstract

cDNA probes for human retinoic acid receptors alpha and beta (RAR alpha and RAR beta) were modified for use as specific hybridization probes to study hepatocellular carcinomas (HCC) and cell lines, liver regeneration, and fetal development. RAR beta mRNA was detected at low levels in adult liver and rose markedly during the early phase of liver regeneration. RAR beta mRNA was present at very low levels in HCC and was not detected in fetal liver. In contrast, RAR alpha mRNA was present at low levels in normal liver, but showed a marked elevation in several HCCs and cell lines. Growth of cell lines was altered by retinoic acid (RA), but the effects could not be predicted by the levels of either RAR alpha or RAR beta mRNA. However, the response correlated with cell phenotype. Three cell lines with an adult phenotype (high albumin and low alpha-fetoprotein) were inhibited by RA, two undifferentiated lines showed moderate growth stimulation, and two of three cell lines that had high levels of alpha-fetoprotein were markedly stimulated by RA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710463     DOI: 10.1002/mc.2940040209

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  13 in total

1.  4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.

Authors:  K Murakami; T Matsuura; M Sano; A Hashimoto; K Yonekura; R Sakukawa; Y Yamada; I Saiki
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

2.  Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Shun-Yuan Jiang; Jung-Mao Chou; Fur-Jiang Leu; Yu-Yen Hsu; Yu-Lung Shih; Jyh-Cherng Yu; Meei-Shyuan Lee; Rong-Yaun Shyu
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

Review 3.  Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Authors:  Jaleh Varshosaz; Maryam Farzan
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

4.  Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157).

Authors:  F L Meyskens; J Jacobson; B Nguyen; G R Weiss; D R Gandara; J S MacDonald
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

5.  Retinoic acid regulates cell cycle genes and accelerates normal mouse liver regeneration.

Authors:  Hui-Xin Liu; Irene Ly; Ying Hu; Yu-Jui Yvonne Wan
Journal:  Biochem Pharmacol       Date:  2014-08-01       Impact factor: 5.858

6.  Integration of growth factor, extracellular matrix, and retinoid signals during bronchial epithelial cell differentiation.

Authors:  N Moghal; B G Neel
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

7.  Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer.

Authors:  N Moghal; B G Neel
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

8.  Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis.

Authors:  Masahito Shimizu; Yohei Shirakami; Kenji Imai; Koji Takai; Hisataka Moriwaki
Journal:  J Carcinog       Date:  2012-08-30

9.  Acyclic retinoid induces differentiation and apoptosis of murine hepatic stem cells.

Authors:  Hong-Bin Guan; Yun-Zhong Nie; Yun-Wen Zheng; Kazuya Takiguchi; Hong-Wei Yu; Ran-Ran Zhang; Bin Li; Tomonori Tsuchida; Hideki Taniguchi
Journal:  Stem Cell Res Ther       Date:  2015-03-26       Impact factor: 6.832

10.  The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma.

Authors:  Shuaishuai Zhang; Weiwei Gao; Juan Tang; Huaifang Zhang; Yuqi Zhou; Jie Liu; Kun Chen; Fangzhou Liu; Wengang Li; Sally K Y To; Alice Sze Tsai Wong; Xiao-Kun Zhang; Hu Zhou; Jin-Zhang Zeng
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.